Detalhe da pesquisa
1.
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Clin Exp Immunol
; 211(3): 280-287, 2023 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36729167
2.
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Lancet
; 398(10304): 981-990, 2021 09 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480858
3.
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study.
Lancet Infect Dis
; 24(5): 465-475, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38342107
4.
Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.
Wellcome Open Res
; 8: 450, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38813551
5.
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial.
Lancet Microbe
; 3(9): e663-e671, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35907430
6.
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
EBioMedicine
; 85: 104298, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36229342
7.
Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial.
Lancet Microbe
; 3(1): e11-e20, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34751259
8.
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.
Lancet Infect Dis
; 22(12): 1728-1736, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36087586
9.
Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies.
Vaccines (Basel)
; 9(3)2021 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33809415
10.
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Nat Med
; 27(2): 270-278, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33335323
11.
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Nat Med
; 27(6): 1116, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34021278